Kamada Ltd. (NASDAQ:KMDA - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 earnings per share estimates for Kamada in a note issued to investors on Thursday, November 14th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will earn $0.25 per share for the year, down from their previous estimate of $0.28. HC Wainwright has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for Kamada's current full-year earnings is $0.24 per share.
Separately, StockNews.com cut shares of Kamada from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, August 27th.
Check Out Our Latest Report on KMDA
Kamada Trading Up 2.4 %
Shares of Kamada stock traded up $0.14 during trading on Monday, hitting $5.95. 93,992 shares of the stock were exchanged, compared to its average volume of 30,144. The company has a fifty day moving average price of $5.48 and a 200-day moving average price of $5.47. The stock has a market capitalization of $342.01 million, a price-to-earnings ratio of 20.75 and a beta of 1.05. Kamada has a 1-year low of $4.60 and a 1-year high of $6.53.
Institutional Trading of Kamada
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Public Employees Retirement System of Ohio bought a new position in Kamada in the 3rd quarter valued at approximately $77,000. Plato Investment Management Ltd acquired a new position in shares of Kamada during the third quarter worth $117,000. Vanguard Group Inc. lifted its stake in shares of Kamada by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company's stock valued at $7,433,000 after acquiring an additional 100,800 shares during the last quarter. Finally, Y.D. More Investments Ltd boosted its holdings in shares of Kamada by 1,956.0% during the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company's stock valued at $3,643,000 after acquiring an additional 690,842 shares in the last quarter. Institutional investors own 20.38% of the company's stock.
About Kamada
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
See Also
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
